Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded ...
Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results